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Interview: Duncan Campbell
After the draft sequence, what next for the Human
Genome Mapping Project Resource Centre?
Dr R. Duncan Campbell is the Director of the Medical Research Council (MRC) funded UK Human Genome Mapping
Project Resource Centre (HGMP-RC), on the Wellcome Trust Genome Campus at Hinxton, near Cambridge, UK. The
Centre provides both biological and bioinformatics resources to the UK genomics community, and also has research
groups supporting these activities and investigating separate projects.
CFG: The HGMP-RC is broadly arranged into three
Divisions: Bioinformatics, Biology Services and
Research. Let’s tackle these one at a time. The
draft sequence release will no doubt have encouraged
many researchers to get on-line and use bio-
informatics tools to mine the dataset, can you tell
me about the projects that the Bioinformatics team
are working on to facilitate such investigations?
RDC: With the huge amount of draft sequence now
available, we have seen increased use of the
bioinformatics tools already on offer from the
HGMP-RC, such as NIX and PIX. NIX is a suite
of programs for database screening by BLAST,
repeat masking and exon prediction for the identi-
ﬁcation of genes from genomic sequences. PIX is a
protein equivalent of NIX, with BLAST searches,
programs for domain and sequence motif detection,
prediction of secondary structure and other tools.
We are currently working on tools for microarray
bioinformatics. Microarrays are clearly a very
important research tool since they allow monitoring
of the expression levels of large numbers of genes in
parallel. We are developing tools, which will hope-
fully become available shortly, to support the use of
the microarray service which we have set up. In
addition to providing improved tools for data
acquisition we will offer a public database to
facilitate mining of the microarray data. We are
also continuing to develop EMBOSS, a suite of
tools for DNA and protein sequence analysis,
which will expand the functions offered by the
Genetics Computer Group (GCG) package. We are
currently redeveloping our website in order to make
it bigger, better and more interactive for our users,
and our hope is that we will have a new website
which will go live in the next few months. The site
will include access and ordering for the existing
services and information and support for new
services as they come on-line.
CFG: The Biology Services Division supplies a
continuously expanding range of clone libraries, and
hosts a Linkage Hotel, which enables groups to send
a lab member to the HGMP-RC to perform genetic
screens for their loci of interest. Are there any new
plans for this Division in the light of the genome
draft? Will the Linkage Hotel continue to be
available; do you see a shift away from genetic
screens, or are there still plenty of loci out there
waiting to be pinned down?
RDC: There certainly are plenty of disease loci still
waiting to be pinned down, but what I think will
change is how the screening will be done. So far we
have used microsatellites in our genotyping, but we
are now shifting towards using Single Nucleotide
Polymorphisms (SNPs). That is not to say that we
will stop using microsatellites, they have proved to
be a very useful tool for genetic linkage studies. In
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area, from the current 0.5 million genotypes, up to
1–1.5 million microsatellite genotypes. We are
currently looking very seriously at SNP analysis,
since SNPs offer a lot of advantages over micro-
satellites, partly because of their increased density,
but also because they can alter gene expression if
they are located in the UTRs, and can alter gene
function if they are located in the coding sequence.
SNP analysis will provide a tremendous amount of
useful information, but at the moment we need to
select a platform for SNP genotyping. A range of
options are available, including Mass Spectrometry,
ﬂuorescent capillary sequencing, Invader and
Taqman approaches and we are validating these
alternatives to decide which one we will use. We are
aiming to combine high-throughput (that is to say
the ability to do tens of thousands of SNP
genotypes a day) with the best cost, to allow us to
provide a service similar to what we offer for
microsatellite screening.
Another key aspect of Biology Services in the
past has been supplying clones such as BACs and
cDNAs. We are currently expanding our range of
full-length cDNA resources, and are distributing
human and mouse cDNA clones as part of the
Mammalian Gene Collection (Strausberg et al.,
(1999). We are also supplying resources that are
important for functional genomics; for example,
another addition is a C. elegans RNAi resource
made by Julie Ahringer’s laboratory in Cambridge
(UK) for suppression of the expression of each gene
across C. elegans chromosome I (Fraser et al.,
(2000). We are also making microarrays by PCR
ampliﬁcation of cDNA inserts and spotting onto
glass slides. The PCR products are from human and
mouse cDNA libraries and will be made available
through Biology Services.
The activities which Biology Services are involved
in are continually expanding; in order to cope with
this expansion, the Division will be moving to larger
premises at the Babraham Campus. We have also
obtained additional funding from the MRC for
further posts to support the increased demand for
resources and genotyping. Our main aim (which can
be quite a daunting task in the fast moving ﬁeld of
functional genomics) is to keep pace with the new
types of services and resources needed by the
research community.
CFG: Many of the interests of the Research Division
stem from your long-standing interest in the Major
Histocompatibility Complex (MHC) class III region.
Perhapsyoucouldgiveourreadersabriefbackgrounder
on this interesting region of the human genome?
RDC: The MHC spans about 4 Mb of DNA and
contains around 224 loci, at least 128 of which
are predicted to be expressed (MHC Sequencing
Consortium, (1999). The class III region is just over
800 kb long and contains 61 loci, it is the most gene
dense region in the human genome. The MHC
region is of interest, not only because of the large
number of genes involved in immune and inﬂam-
matory responses, but also because many human
autoimmune diseases show genetic susceptibility
mapping to this region. One of the key things we
want to do is identify which of the genes are
involved in these diseases. One way to do this is to
look for SNPs in the genes and then genotype them
in DNA from patients to see if they have a role in
the disease. The SNPs located within genes and
their control regions are the best candidates for
these studies as they are most likely to affect gene
function. A crucial part of this research is to have
accesstoDNAfromlargepatientpopulations,andwe
already have important collaborations, for example
withJohnTodd,whohas alargecollectionof diabetes
patient samples and Dominic Kwiatkowski who has
samples wecan use toassess the effects of MHC SNPs
onmalariasusceptibility.Wewouldlike toexpand the
range of diseases we are screening our SNPs against
and we are keen to set up new collaborations that
would enable us to look at diseases such as RA and
multiple sclerosis.
CFG: There are several functional genomics research
projects underway at the HGMP-RC using genes
from the MHC class III region as models for
mechanisms that might be genome wide, can you tell
us a little about these projects?
RDC: One of the great things about genes in the
class III region is that they illustrate all of the same
features as genes from around the genome that one
might want to investigate. The region is very gene
dense; the genes are very close together, with some
overlapping at their 5k ends and some at their 3k
ends, so there are going to be some very interesting
aspects of the regulation of these genes. There is a
large amount of alternative splicing of the class III
genes. At least 40% of genes analysed undergo
alternative splicing, with a wide range of complexity,
from having two or three splice variants, all the way
Interview: Duncan Campbell 177
Copyright # 2001 John Wiley & Sons, Ltd. Comp Funct Genom 2001; 2: 176–179.up to 21, in the case of one particular gene. In most of
those genes that we have studied, the splice variation
affects the amino acid sequence and therefore may
well affect the function of the gene products.
Class III gene products exhibit a wide range of
subcellular localisations, from the cytoplasm, to the
nucleus, to the cell surface. We are using and
developing a range of techniques to look at the
functions of these proteins; for the cell surface
proteins we are looking at the ligands that they bind
and the intracellular pathways that they activate.
We are also using yeast 2-Hybrid screens and
developing them into a high throughput mode to
identify the interacting partners of the intracellular
proteins. Finally, we are systematically tagging each
of the encoded proteins to deﬁne their subcellular
location. This approach will facilitate afﬁnity puriﬁ-
cation of expressed proteins and interacting partners.
CFG: The research division also has groups working
on other genomes: the mouse sequencing group and
the Fugu genomics group. The mouse sequencing
group has joined in the project to sequence the mouse
genome, can you tell me more about that? Do you
have any plans to exploit their data?
RDC: The mouse sequencing group is acting as part
of the MRC funded UK Mouse Sequencing
Programme, which includes the Sanger Centre, the
MRC Mammalian Genetics Unit and UK Mouse
Genome Centre at Harwell, the MRC Human
Genetics Unit (HGU) in Edinburgh and Imperial
College in London. The consortium is focussed on
generating ﬁnished sequence for four regions of the
mouse genome, on chromosomes 2, 4, 13 and X,
which underpin work at Harwell and HGU. The
HGMP-RC will generate 25 Mb of ﬁnished
sequence and the Sanger centre will produce a
further 25 Mb of sequence. Harwell and HGU
supply mapped clones to the HGMP-RC, and the
sequence data generated here is annotated by the
ENSEMBL group at the European Bioinformatics
Institute (EBI). Like the human genome data, it is
also deposited in the public databases to become
part of the larger international effort. Harwell and
HGU will then use this data to identify genes that
cause the phenotypes they have already been
studying in their mouse models.
CFG: Sequencing Fugu cosmids was initially sug-
gested (and quite widely taken up) as a faster
alternative for gene identiﬁcation than sequencing
human clones. I expect that the availability of the
draft sequence will have changed the emphasis of the
Fugu Genomics group; can you tell us what role you
now see it playing?
RDC: The Joint Genome Institute (JGI) of the US
Department of Energy, the Institute for Systems
Biology (in Seattle, USA), Greg Elgar’s group here
at the HGMP-RC and the Institute for Molecular
and Cell Biology (in Singapore) have formed a
consortium to generate a draft sequence of the Fugu
genome. That will be very important because it will
allow a three-way comparison between human,
mouse and Fugu genomic DNA. In the last year,
Greg’s team have already shown that these types of
comparisons allow easier identiﬁcation not only of
coding sequences, but can also reveal enhancers and
regulatory sequences in the promoter regions and
introns of genes. In some cases, there is a stronger
contrast in the sequence conservation with Fugu,
which helps to highlight these regions better than
the human and mouse comparison alone.
In addition to generating the Fugu genome
sequence, the group is also involved in the develop-
ment of new software tools to facilitate the
identiﬁcation of regulatory regions. They are
repackaging and developing existing sequence com-
parison tools as well as the new tools, for analysis
and visualisation of these three way comparisons.
CFG: You have mentioned a microarray group, can
you give us more detail on what services you hope to
provide to the community and which technologies are
you considering offering?
RDC: The ability to use microarrays to look at the
expression of tens of thousands of genes is one of
the key technologies in functional genomics.
Through Tom Freeman we have set up a micro-
array group here, which is producing human and
mouse microarrays on glass slides, loaded with
PCR ampliﬁed products from cDNA clones. One of
our aims is to provide the PCR products from the
cDNA clones, in addition to the microarrays
themselves, to the community, for use in their own
work. We also want to provide informatics support
for this service, including tools for data analysis and
encouraging deposition of the data into a database
and providing opportunities for data mining. This is
a fast moving ﬁeld and another aspect of the remit
of the group is to keep up with the current
technologies. In addition to supplying the glass
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Affymetrix GeneChip system and provide access to
this via a ‘Microarray Hotel’, run in a similar way
to the Linkage Hotel system. We will work with
those groups who choose to use the arrays, they will
get advice and support on aspects such as preparing
their RNA samples (to the high quality which is
crucial for obtaining meaningful results), and we
will supply protocols and other support information
with the slides and through our website.
CFG: An important part of your role is keeping up to
date with new techniques and approaches for functional
genomics, so I’m sure there are other new projects in
the pipeline that you would like to tell us about, are
you looking at proteomics for example?
RDC: Research projects for the future include
expanding our capabilities in proteomics, including
developing tools for in silico predictions of protein
function and protein-protein interactions and
continuing to develop our high throughput yeast
2-Hybrid systems for detection of interacting
protein pairs. We will also be doing 1D and 2D-
gel analysis of whole cell protein extracts and
further immunoprecipitations of tagged protein
complexes, these will be followed by Mass Spectro-
metric identiﬁcation of the proteins. We are also
looking at novel developments in proteomics such
as phage-antibody based arrays and protein arrays
to see how these can be incorporated into the
research work we are doing and also how these
might be supplied, or provided as services, to the
community in the future.
Related websites
UK HGMP-RC
http://www.hgmp.mrc.ac.uk/
Mammalian Gene Collection
http://mgc.nci.nih.gov/
Todd lab webpage – Diabetes Genetics
http://diesel.cimr.cam.ac.uk/todd/
Kwiatkowski lab webpage – Malaria Genetics
http://www.well.ox.ac.uk/malaria/malaria_genetics.htm
UK Mouse Sequencing Programme
http://mrcseq.har.mrc.ac.uk/
The Sanger Centre
http://www.sanger.ac.uk/
MRC Mammalian Genetics Unit and UK
Mouse Genome Centre
http://www.har.mrc.ac.uk/
MRC Human Genetics Unit
http://www.hgu.mrc.ac.uk/
Imperial College of Science, Technology and
Medicine
http://www.ic.ac.uk/templates/front_index_3.asp?P=178
The European Bioinformatics Institute (EBI)
http://www.ebi.ac.uk
The Joint Genome Institute (JGI)
http://jgi.doe.gov/tempweb/
The Institute for Systems Biology
http://www.systemsbiology.org/
Institute for Molecular and Cell Biology
http://www.imcb.nus.edu.sg/index.shtml
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The Interview articles of Comparative and Functional Genomics aim to present a commentary on topical
issues in genomics studies. They are a personal critical analysis, by the interviewee, of current work in their
ﬁeld of expertise, and aim at providing implications for future genomics studies. This interview was
undertaken by the Managing Editor, Dr Joanne Wixon.
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